Condition

Breast Cancer, Estrogen Receptor-Positive

ClinicalTrials.gov condition label

Clinical trials3

Recruiting0

Common interventions4

Lead sponsors shown3

Clinical trials

3 shown

A Study Evaluating the Efficacy and Safety of De Trastuzumab (T-DXd) in Combination with Immunotherapy for the Neoadjuvant Treatment of HR-positive HER2 Low-expressing Chinese Patients with Early-stage Breast CancerNCT06733233 · 2025-01-01

NOT_YET_RECRUITING

Validity of Brain Metastasis Risk Predictive Model in Hormone Positive Breast Cancer PatientsNCT06729099 · 2025-01-01

NOT_YET_RECRUITING

Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast CancerNCT00676663 · 2008-06-13

Common interventions

entinostatDRUG1 exemestaneDRUG1 PlaceboDRUG1 T-DXd combined with immune checkpoint inhibitorDRUG1

Leading sponsors

Assiut University1 Guangzhou Women and Children's Medical Center1 Syndax Pharmaceuticals1

Trial status mix

NOT_YET_RECRUITING2

COMPLETED1

Phase mix

PHASE22

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.